Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Recommendation is based on pivotal data from the phase III POLARIX study
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
